You are here: Home » News-CM » Economy » News
Business Standard

CCRAS has undertaken several projects to develop medicines for chronic and lifestyle diseases

Capital Market 

The technology related to the drug developed by Central Council for Research in Ayurvedic Sciences (CCRAS), namely, AYUSH-82 has been given to eight manufacturing firms through National Research Development Corporation (NRDC), Dept. of Scientific & Industrial Research, Ministry of Science & Technology, Government of India. The scientific study on AYUSH-82 carried out by CCRAS has shown encouraging results.

CCRAS has developed medicine for other Chronic diseases like arthritis and cancer.

CCRAS has developed AYUSH-SG (Sunthi Guggulu) for Arthritis and the technology has been transferred to five firms through NRDC and is available in the market.

Projects on AYUSH -QOL2C for improving quality of life in cancer patients and AYUSH-Manas in Mental Retardation have been recently concluded. Further, CCRAS has undertaken work for developing AYUSH-SL for Lymphatic Filariasis, AYUSH-D for Diabetes Mellitus, Carctol-S for Ovarian Cancer and AYUSH M-3 for Migrane.

The Ministry of AYUSH through its research organizations. namely, Central Council for Research in Ayurvedic Sciences (CCRAS), Central Council for Research in Unani Medicine (CCRUM), and Central Council for Research in Homoeopathy (CCRH) have launched a pilot programme to integrate Ayurveda, Homoeopathy and Unani with National Programme for prevention and Control of Cancer, Diabetes, Cardiovascular diseases and Stroke (NPCDCS). Initially the pilot study has been started in six districts.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, March 24 2017. 18:37 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU